Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice
about
Brief History and Characterization of Enhanced Respiratory Syncytial Virus DiseaseSynthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial VirusInfluenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing.Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis.Ginseng diminishes lung disease in mice immunized with formalin-inactivated respiratory syncytial virus after challenge by modulating host immune responses.Evaluation of an intranasal virosomal vaccine against respiratory syncytial virus in mice: effect of TLR2 and NOD2 ligands on induction of systemic and mucosal immune responses.Virus-like nanoparticle and DNA vaccination confers protection against respiratory syncytial virus by modulating innate and adaptive immune cells.Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease.Mammalian Cell-Derived Respiratory Syncytial Virus-Like Particles Protect the Lower as well as the Upper Respiratory TractAlum Adjuvant Enhances Protection against Respiratory Syncytial Virus but Exacerbates Pulmonary Inflammation by Modulating Multiple Innate and Adaptive Immune CellsA virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton ratsTopical CpG Oligodeoxynucleotide Adjuvant Enhances the Adaptive Immune Response against Influenza A Infections.Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease.T cell responses to viral infections - opportunities for Peptide vaccination.Respiratory syncytial virus: current progress in vaccine development.Respiratory syncytial virus--a comprehensive review.Influenza virosomes as vaccine adjuvant and carrier system.Advances in and the potential of vaccines for respiratory syncytial virus.The common cold: potential for future prevention or cure.Novel therapies and vaccines against the human respiratory syncytial virus.Liposomal adjuvants for human vaccines.Respiratory syncytial virus vaccines: an update on those in the immediate pipeline.A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.Age-Specific Adjuvant Synergy: Dual TLR7/8 and Mincle Activation of Human Newborn Dendritic Cells Enables Th1 Polarization.The effect of dietary bovine colostrum on respiratory syncytial virus infection and immune responses following the infection in the mouse.Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus.The next-generation nicotine vaccine: a novel and potent hybrid nanoparticle-based nicotine vaccine.Anti-RSV Peptide-Loaded Liposomes for the Inhibition of Respiratory Syncytial Virus.
P2860
Q26775152-97A4B955-AEF5-4116-AD54-0B0205EC1417Q28067143-20DE764A-E76A-4C42-A0EC-FDADD939162CQ30353863-ECFDAE19-FC92-43DD-ABF1-D0D52EE5D61EQ34224973-E8E6D199-CE8E-4FC0-99E9-24BD4E5CFC22Q34440116-44F368A4-67AE-4246-B6C6-2EA2EC016ADFQ34674831-C330DB9D-02F8-491E-8A01-8C6C14F73CF4Q34791209-9580F6E2-E921-4C4D-99E8-7227FA260064Q34990420-E63EC3BE-8903-4B4A-A9C2-04870D33153FQ35690781-2641F6A7-BFD0-43F0-AA7A-5655FBD964E0Q35808047-4CAF5EEA-CD25-481A-9D96-CDB291ADE1ECQ36251566-065B125E-A1D0-4BD3-B99A-DE43808CFE78Q37136591-4B916C5A-ED1E-4465-9BB8-3F734C8CB07FQ37649439-2BA96DD6-A9C1-48B2-AF70-53AC0AC6C2A2Q37718978-9E7C0C72-C7BD-4528-B0C4-821B5C54C188Q38079432-85BE6525-8E49-4C3E-A7E9-21A0C4C0D898Q38098094-64DA3752-6078-40CB-AB1F-E39DA37B2018Q38124062-F9BCFD1F-F0C6-4FBC-A0EC-B3A7B4AFEE4AQ38130514-7A2CEEFC-FE7D-4661-9111-0CFA0994B7B9Q38177756-F042B72B-6186-4035-BE72-1788C40319A5Q38604787-B0E20CC9-C107-45B7-AFD2-1451A8659536Q38729260-485C007E-A590-47D2-ADCF-A70E4E8599A1Q38803541-8223F33C-1233-4C42-B833-73CB19ABAA42Q38905050-CE43F9A9-FD16-462A-B81F-A21F8CC574C9Q40468799-05D6E8DE-C4B0-4CC5-9C3B-B1445FF4B71EQ41032140-D5509DFB-2986-4E4F-845C-436E5DEE46DFQ42138587-2F466960-E0B6-410F-8AAC-914A9BF9DF2FQ42627924-59F66105-2C63-4A87-92D3-F0D64A5DE9FDQ54215285-7B595774-57FA-4E67-A206-7DA50C903131
P2860
Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Immunogenicity and protective ...... monophosphoryl lipid A in mice
@ast
Immunogenicity and protective ...... monophosphoryl lipid A in mice
@en
Immunogenicity and protective ...... monophosphoryl lipid A in mice
@nl
type
label
Immunogenicity and protective ...... monophosphoryl lipid A in mice
@ast
Immunogenicity and protective ...... monophosphoryl lipid A in mice
@en
Immunogenicity and protective ...... monophosphoryl lipid A in mice
@nl
prefLabel
Immunogenicity and protective ...... monophosphoryl lipid A in mice
@ast
Immunogenicity and protective ...... monophosphoryl lipid A in mice
@en
Immunogenicity and protective ...... monophosphoryl lipid A in mice
@nl
P2093
P2860
P3181
P1433
P1476
Immunogenicity and protective ...... monophosphoryl lipid A in mice
@en
P2093
Aalzen de Haan
Julia Lederhofer
Tobias Kamphuis
Toon Stegmann
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0036812
P407
P577
2012-01-01T00:00:00Z